Similar articles for PMID: 31023335

Year	Number of Results
2004	1
2006	1
2013	4
2014	2
2015	5
2016	12
2017	12
2018	5
2019	16
2020	24
2021	21
2022	3
2023	2
2024	0

1

Emerging therapies for non-small cell lung cancer.

Zhang C, Leighl NB, Wu YL, Zhong WZ. Zhang C, et al. J Hematol Oncol. 2019 Apr 25;12(1):45. doi: 10.1186/s13045-019-0731-8. J Hematol Oncol. 2019. PMID: 31023335 Free PMC article. Review.

2

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q. Melosky B, et al. Oncologist. 2020 Jan;25(1):64-77. doi: 10.1634/theoncologist.2019-0027. Epub 2019 May 28. Oncologist. 2020. PMID: 31138727 Free PMC article. Clinical Trial.

3

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.

Lu S, Yu Y, Yang Y. Lu S, et al. Oncologist. 2019 Feb;24(Suppl 1):S21-S30. doi: 10.1634/theoncologist.2019-IO-S1-s02. Oncologist. 2019. PMID: 30819828 Free PMC article. Review.

4

Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.

Smit HJM, Aerts J, van den Heuvel M, Hiltermann TJN, Bahce I, Smit EF, Dingemans AC, Hendriks LE, Stigt JA, Schramel FMNH, van Tinteren H, Groen HJM; all participants of NVALT Immunotherapy Register (see addendum). Smit HJM, et al. Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 Dec 28. Lung Cancer. 2020. PMID: 31911323 Free article.

5

Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.

Medikonda R, Pant A, Lim M. Medikonda R, et al. Adv Exp Med Biol. 2023;1394:73-84. doi: 10.1007/978-3-031-14732-6_5. Adv Exp Med Biol. 2023. PMID: 36587382

6

Immunotherapy in Advanced Non-Small Cell Lung Cancer.

Huang J, Reckamp KL. Huang J, et al. Semin Respir Crit Care Med. 2020 Jun;41(3):400-408. doi: 10.1055/s-0040-1710077. Epub 2020 May 25. Semin Respir Crit Care Med. 2020. PMID: 32450594 Review.

7

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.

Nagano T, Tachihara M, Nishimura Y. Nagano T, et al. Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559. Curr Cancer Drug Targets. 2019. PMID: 30526458 Review.

8

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.

Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K. Rybarczyk-Kasiuchnicz A, et al. Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593. Int J Mol Sci. 2021. PMID: 33435596 Free PMC article. Review.

9

Emerging therapeutic agents for advanced non-small cell lung cancer.

Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Chen R, et al. J Hematol Oncol. 2020 May 24;13(1):58. doi: 10.1186/s13045-020-00881-7. J Hematol Oncol. 2020. PMID: 32448366 Free PMC article. Review.

10

[Advances in Hyperprogressive Disease in Patients  with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].

Yao S, Shi K, Zhang Y. Yao S, et al. Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):271-278. doi: 10.3779/j.issn.1009-3419.2021.101.08. Zhongguo Fei Ai Za Zhi. 2021. PMID: 33910275 Free PMC article. Review. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year